University of Illinois-Urbana-Champaign,
Urbana-Champaign, IL – 1988
Ms. Helfrich has been a member of the Division of Medical Oncology since 1992. Her research focus is translation of molecularly targeted drugs from the bench to the bedside for the treatment of lung cancer patients.
Ms. Helfrich’s focus is lung cancer research. She investigates the efficacy of novel molecularly targeted agents in both non-small cell (NSCLC) and small cell lung cancer (SCLC). Following the determination of drug efficacy in a large panel of lung cancer cell lines she attempts to determine biomarkers that can then be used in clinical trials to select patients that are most likely to respond to the novel agent.
Camidge DR, Skokan M, Kiatsimkul P, Helfrich B, Lu X, Baron AE, Schulte N, Maxson D, Aisner DL, Franklin WA, Doebele RC, Varella-Garcia M. Native and rearranged ALK copy number and rearranged cell count in nonsmall cell lung cancer. 2013 Cancer ePub 3968-3975.
Ware KE, Hinz TK, Kleczko E, Singleton KR, Marek LA, Helfrich BA, Cummings CT, Graham DK, Astling D, Tan AC, Heasley LE. A mechanism of resistance to gefitinib medicated by cellular reprogramming and the acquisition of an FGF2-FGFR1 autocrine growth loop. 2013 Oncogenesis 2.e39 1-9.
Co-Investigator: Development and Testing of Neuropeptide Signal Pathways for the Treatment and Chemoprevention of Lung Cancer: Funding Source: National Cancer Institute 9/30/92-5/30/14
Co-Investigator: In vitro evaluation of Halavan in a panel of SCLC cell lines with Affymetrix gene expression profiles. Funding Source: Eisai Inc, Woodcliff Lake, NJ 2/13-2/15.